Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S093200, C424S093210, C536S023500
Reexamination Certificate
active
09730790
ABSTRACT:
The invention provides a clinically useful protocol for delivery of recombinant nervous system growth factors into the aging mammalian brain. The invention is particularly useful in tempering and reversing the loss of neurological function in the aging mammalian brain, by (a) correlating loss of cortical fiber density to impairment of neurological function in the normal, aging brain; and (b) providing minimally invasive means by which such losses may be reversed. To these ends, a method is provided by which a growth factor-encoding transgene is delivered to, and expressed in, preselected sites within the brain, to stimulate growth of neurons at, and at a distance from, each delivery site.
REFERENCES:
patent: 5082670 (1992-01-01), Gage et al.
patent: 5529774 (1996-06-01), Barba et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5650148 (1997-07-01), Gage et al.
patent: 5683695 (1997-11-01), Shen et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5762926 (1998-06-01), Gage et al.
patent: 6451306 (2002-09-01), Tuszynski et al.
patent: 6683058 (2004-01-01), Tuszynski
patent: WO 90/06757 (1990-06-01), None
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Verma et al., 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki, 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
Castro et al., 2001, Histl. Histopathol., vol. 16, p. 1225-1238.
Mandel et al., 1999, Experimental Neurology, vol. 155, No. 1, pp. 59-64.
Kojima, et al., “Adenovirus-Mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain,”Biochemical and Biophysical Research Communications, 238:569-573 (1997).
Roberts, et al., “Effects of NGF-Secreting Genetically Modified Cell Grafts on Cholinergic Neuronal Morphology and Gocnition in Aged Primates,”Soc. For Neuroscience Abstracts, 21(2):613.8 (1995).
Yang, et al., “Gene Therapy for Central Nervous System Injury: The Use of Cationic Liposomes: An Invited Review,”Journal of Neurotrauma, 14(5):281-297 (1997).
Zlokovic, et al., “Cellular and Molecular Neurosurgery: Pathways From Concept to Reality—Part II: Vector Systems and Delivery Methodologies for Gene Therapy of The Central Nervous System,”Neurosurgery, 40(4):805-813 (1997).
Armelin et al., “Pituitary extracts and steroid hormones in the control of 3T3 cell growth”Proc. Natl. Acad. Sci. (1973) 70:2702-6.
Banerji et al., “Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences”Cell(1981) 27:299-308.
Benoist et al., “In vivo sequence requirements of the SV40 early promoter region”Nature(1981) 290:304-10.
Blesch et al., “Ex vivo gene therapy for Alzheimer's disease and spinal cord injury”Clinical Neuroscience(1996) 3:268-274.
Borsani et al., “cDNA sequence of human beta-NGF”Nucleic Acids Res. (1990) 18:4020.
Breathnach et al., “Organization and expression of eucaryotic split genes coding for proteins”Ann. Rev. Biochem. (1981) 50:349-83.
Chen et al., “Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA”BioTechniques(1988) 6:632-8.
Chen et al., “High-efficiency transformation of mammalian cells by plasmid DNA”Mol. Cell. Biol. (1987) 7:2745-52.
Chua et al., “Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts”Connect. Tissue Res. (1990) 25:161-170.
Conner et al., “Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions”Society for Neuroscience(1997) 23:53 Abstract 29.5.
Corden et al., “Promoter sequences of eukaryotic protein-coding genes.”Science(1980) 209:1406-14.
DePamphilis et al., “Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals”BioTechniques(1988) 6:662-80.
de Wet et al., “The mRNAs for the pro-alpha 1(I) and pro-alpha 2(I) chains of type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs”J. Biol. Chem. (1983) 258:14385-9.
Elias et al., “Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma”Ann. N.Y. Acad. Sci. (1990) 580:233-244.
Felgner et al., “Cationic liposome mediated transfection”Proc. West. Pharmacol. Soc. (1989) 32:115-21.
Felgner et al., “Cationic liposome mediated transfection”Focus. (1989) 11:21-25.
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure”Proc. Natl. Acad. Sci. (1987) 84:7413-7.
Fraley et al., “New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids”Trends Biochem. Sci. (1981) 6:77-80.
Fromm et al., “Deletion mapping of DNA regions required SV40 early region promoter function in vivo”J. Mol. Appl. Genet. (1982) 1:457-81.
Gruss et al., “Simian virus 40 tandem repeated sequences as an element of the early promoter”Proc. Natl. Acad. Sci. (1981) 78:943-7.
Hefti et al., “Nerve growth factor and Alzheimer's disease”Ann. Neurol. (1986) 20:275-81.
Higgins et al., “NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease”Exp. Neurol. (1989) 106:222-36.
Horellou et al., “Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease”Experimental Neurobiology(1997) 144:131-8.
Jolly et al., “Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene”Nucleic Acids Res. (1983) 11:1855-1872.
Kobayashi et al., “Morphometric study on the CH$ of the nucleus basalis of Meynert in Alzheimer's disease”Mol. Chem. Neuropathol. (1991) 15:193-206.
Kordower et al., “The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor”Proc. Natl. Acad. Sci. (1994) 91:10898-10902.
Lehericy et al., “Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease”J. Comp. Neurol. (1993) 330:15-31.
Levivier et al., “Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease”The Jo. Of Neuroscience(1995) 15:7810-20.
Mannino et al., “Liposome mediated gene transfer”Biotechniques(1988) 6:682-90.
Maxam et al., “Sequencing end-labeled DNA with base-specific chemical cleavages”Methods in Enzymology(1980) 65:499-560.
McCutchan et al., “Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyl-dextran”J. Natl. Cancer Inst. (1968) 41:351-7.
Messing et al., “A system for shotgun DNA sequencing”Nucleic Acids Res. (1981) 9:309-21.
Mesulam et al., “Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey.”J. Comp. Neurol. (1983) 214:170-197.
Moreau et al., “The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants”Nucleic Acids Res. (1981) 9:6047-6068.
Mufson et al., “Loss of nerve growth factor receptor-con
Blesch Armin
Tuszynski Mark H.
Chen Shin-Lin
Foley & Lardner LLP
The Regents of the University of California
LandOfFree
Methods for modulation of the effects of aging on the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulation of the effects of aging on the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulation of the effects of aging on the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774822